Gilead Sciences: Still Plenty of Growth Despite 'Stagnated' HepatitisC

Gilead Sciences: Still Plenty of Growth Despite 'Stagnated' HepatitisC
For Gilead, the company's HCV launch in the U.S. has stagnated but there is still plenty of opportunity for ex-U.S. growth. As payors still won't let HCV patients flow through the system easily, Gilead is hoping ongoing education and campaigning will …
Read more here.

Hepatitis C rates in Oregon soar above national average
There are new treatments out for hepatitis C and they're effective. But the problem is they're very expensive, and often people don't know they're infected. It can take decades for symptoms to appear. Among people diagnosed between 2009 and 2013 …
Read more here.

Hepatitis C treatment is cheaper than the alternative
I was glad to read the recent article written by Meredith Cohn about novel therapies for hepatitis C and the trouble that some patients have in affording these drugs ("Hepatitis C drugs can cure — if patients can afford them," July 18, 2015). As an …
Read more here.

Faithfull promotes Hepatitis C awareness week
Singer songwriter Marianne Faithfull is set to front Ireland's first campaign to promote awareness of hepatitis C. The 68-year-old will front The National Hepatitis C Awareness Week. The campaign takes place from July 27 to 31, and Faithfull will be …
Read more here.

Aboriginal people are disproportionately affected by hepatitis. We know why
The over-incarceration of Aboriginal people means that more of us are in an environment where there are very high rates of hepatitis C. We're more likely to inject drugs and share equipment when we do inject drugs, and our historic disconnection from …
Read more here.

Hep C drug is well worth it
Before Sovaldi, hepatitis C drugs only cured about half of patients. Those who didn't respond to treatment were at risk of serious and costly liver complications. A liver transplant costs nearly $ 600,000. These new cures can also save money in the long …
Read more here.

Pricey Successor Overtakes 00-Per-Pill Hepatitis C Drug
The $ 1,000 pill for a liver-wasting viral infection that made headlines last year is no longer the favorite of patients and doctors. The new leading pill for hepatitis C is more expensive, and the number of patients seeking a cure has surged. Sovaldi …
Read more here.

Hepatologists advocate plan to eradicate hepatitis C in Belgium
On Monday, the day before World Hepatitis Day, the CHAC patients association (Carrefour hépatites – aide et contact) stated that it was a question of politics. Hepatitis C affects 170 million people worldwide, including 70,000 Belgians. The virus kills …
Read more here.

Gilead Limits Enrollment in its Hep C Patient Program to Pressure Insurers
In a bid to push back against payers, Gilead Sciences GILD -4.11% is limiting enrollment to its patient assistance program for hepatitis C drugs, which helps people obtain the Sovaldi and Harvoni treatments when they lack sufficient insurance coverage …
Read more here.

Bristol-Myers smashes Q2 as hep C meds rake in overseas sales
It was the company's hepatitis C franchise that delivered the biggest new punch, with sales of $ 479 million. And that's without any sales in the U.S., where Daklinza (daclatasvir) and Sunvepra (asunaprevir) haven't yet won FDA approval. So far this …
Read more here.


Leave a Reply